Physician profile
Ali Mehdi
NPI 1104108570
$75,685.77
in general payments reported to CMS, 2019-2025
15 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2021: $2,513 · 2022: $153 · 2023: $3,541 · 2024: $37K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,780 · Travel and Lodging: $3,740 · Food and Beverage: $1,878 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,513.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,780.00 |
| Travel and Lodging | $3,739.56 |
| Food and Beverage | $1,878.42 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27,106.90 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $25,696.84 | 2020-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $10,640.74 | 2023-2025 | Benlysta |
| Apellis Pharmaceuticals, INC. | $5,751.00 | 2025 | |
| Calliditas Therapeutics US INC. | $3,277.21 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $2,648.69 | 2021-2022 | |
| Amgen INC. | $156.29 | 2025 | Uplizna, Tavneos |
| Travere Therapeutics, INC. | $143.49 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $67.65 | 2025 | |
| Aurinia Pharma U.S., INC. | $45.24 | 2022-2023 | |
| Nxstage Medical, INC. | $43.35 | 2025 | Nxstage System One, Nxstage Pureflow Solution, Nxstage Cartridge Express |
| Mallinckrodt Hospital Products INC. | $32.23 | 2025 | Terlivaz |
| Akebia Therapeutics INC | $27.34 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2025 | Jardiance |
| Outset Medical INC | $22.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.